AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol-Myers

Pharmaceutical giants AstraZeneca plc (NASDAQ:AZN) and Bristol-Myers Squibb Co  (NYSE:BMY) announced new acquisitions today.

Acquisitions Push 2 Pharma Stocks in Opposite Directions

Gracell Biotechnologies acquisition marks China's growing importance to the Anglo-Swedish drugmaker

AstraZeneca buys Chinese cancer therapy firm Gracell for $1.2bn

Gracell Biotechnologies

Dec 26 (Reuters) - AstraZeneca (AZN.L) said on Tuesday it will buy Gracell Biotechnologies (GRCL.O) for up to $1.2 billion as the Anglo-Swedish pharma company furthers its cell therapy ambitions and boosts its presence in China, the world's second-largest pharmaceuticals market.

AstraZeneca to buy China's Gracell Biotechnologies in $1.2 billion deal

AstraZeneca's acquisition of Gracell is expected to close in the first quarter of 2024.

AstraZeneca to Acquire China's Gracell in $1.2 Billion Deal to Further Cell Therapy Goals

Amgen

BioMarin Pharmaceutical

Blueprint Medicines

Karuna Therapeutics Inc

Pfizer

Roche Holding AG

Vertex Pharmaceuticals

SPDR S&P Biotech ETF

A more favorable interest-rate outlook, an uptick in deals, and innovations in key areas like cancer and immunology are setting up biotech for a brighter 2024, analysts say.

Biotech stocks set for a rebound in 2024, analysts say

Eli Lilly

Novartis

Big drug companies want to use artificial intelligence for a handful of purposes. Finding leads to make medicines more efficiently is one in-demand application.

These 3 Big Pharma Stocks Are Making Big Plays With AI

Ionis Pharma

Ionis Pharmaceuticals IONS, +1.61% and AstraZeneca's AZN, +0.79% Wainua has been approved by the U.S. Food and Drug Administration for treating a symptom of a rare genetic disease.

Ionis Pharmaceuticals, AstraZeneca get FDA approval for rare genetic disease treatment

The U.S. Food and Drug Administration (FDA) on Thursday approved Ionis Pharmaceuticals and partner AstraZeneca's drug to treat nerve damage caused by a life-shortening rare disease.

US FDA approves Ionis-AstraZeneca's nerve disease drug

Novo Nordisk

The anti-obesity drug market could be a significant growth opportunity for healthcare companies. Eli Lilly and Novo Nordisk are the big names in the market today, but there could soon be others.

Weighing Their Chances: 5 Leading Healthcare Companies Fight for Market Share in the $100 Billion Weight-Loss Industry

Lloyds Banking Group

Rolls-Royce Holdings PLC

For investors, the focus in 2024 will be on navigating a year expected to be split into distinct halves. That, at least, is the conclusion of Liberum, the boutique investment bank, in assessing the tactics to deploy over the next 12 months.

Lloyds, AstraZeneca, BATs, Rolls-Royce: What's on the menu for 2024?

Compugen

Dosing of first patient in Phase 3 trial of rilvegostomig, a PD-1/TIGIT bispecific antibody, will trigger $10 million milestone payment from AstraZeneca HOLON, Israel , Dec. 19, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced it will be eligible to receive a milestone payment of $10 million from AstraZeneca (LSE/STO/Nasdaq: AZN), when the first patient is dosed in AstraZeneca's ARTEMIDE-Bil01 trial with rilvegostomig.

Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer

In the most recent trading session, Astrazeneca (AZN) closed at $65.95, indicating a +1.77% shift from the previous trading day.

Astrazeneca (AZN) Exceeds Market Returns: Some Facts to Consider

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--The first patient has been dosed in two global, randomized phase 3 trials evaluating the efficacy and safety of Daiichi Sankyo (TSE: 4568) and AstraZeneca's (LSE/STO/Nasdaq: AZN) datopotamab deruxtecan (Dato-DXd) in combination with durvalumab, AstraZeneca's anti-PD-L1 therapy, in two types of breast cancer. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) being jointly developed by Daiichi Sankyo.

Two Phase 3 Trials of Datopotamab Deruxtecan Plus Durvalumab Initiated in Patients Across Two Breast Cancer Subtypes

Sanofi

The makers of a respiratory syncytial virus (RSV) immunization for infants that has been in tight supply will deliver an additional 230,000 doses in January, the White House said on Thursday, after U.S. government officials met with the companies to discuss meeting winter demand.

AstraZeneca, Sanofi to supply 230,000 more RSV infant shots to US market

Icosavax

Shares of Icosavax (ICVX) skyrocketed over 48% in early trading Tuesday after AstraZeneca (AZN) agreed to purchase the biopharma company for $1.1 billion to expand its reach into cutting-edge vaccine technology.

Why AstraZeneca Is Buying Icosavax For $1.1 Billion

AstraZeneca (AZN) is set to acquire clinical-stage biopharmaceutical company, Icosavax, for a total deal value of up to $1.1 billion.

AstraZeneca (AZN) to Acquire Vaccine Maker Icosavax for $1.1B

Seattle-based Icosavax, a spin-out from the University of Washington's Institute for Protein Design, will be acquired by biotech giant AstraZeneca for up to $1.

AstraZeneca will pay up to $1.1B to acquire Icosavax, a Univ. of Washington biotech spinout

Britain's biggest drugmaker buying Seattle-based firm Icosavax, expanding vaccine and immune therapy business

AstraZeneca buys US vaccine company in $1.1bn deal

Vaccines specialist Icosavax Inc (NASDAQ: ICVX) is set to surge 45% on Tuesday after agreeing to be taken over by Anglo-Swedish pharma group AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) for $838 million cash up front, potentially rising to $1.1 billion.  Having closed at $10.51 yesterday, the stock jumped to $15.25 in pre-market trading this morning, above the offer price of $15.00 per share.

Icosavax surges 45% in pre-market trading as AstraZeneca agrees takeover

AstraZeneca agreed to acquire respiratory vaccine developer Icosavax in a cash deal expected to close in the first quarter of next year.

This Vaccine Stock Soars 46% After $1.1 Billion AstraZeneca Deal

AstraZeneca has agreed to acquire U.S.-based vaccine developer Icosavax for $1.1 billion, the companies announced Tuesday, to gain access to experimental vaccines targeting common respiratory disease-causing viruses.

AstraZeneca Will Acquire RSV Vaccine Developer Icosavax For $1.1 Billion

AstraZeneca has bought US biopharmaceutical company, Icosavax Inc, for up to $1.1 billion.  The Anglo-Swedish drugs maker said the deal will build on its expertise in respiratory syncytial virus (RSV), and strengthen its Vaccines & Immune Therapies late-stage pipeline with Icosavax's lead investigational vaccine candidate, IVX-A12.

AstraZeneca boosts RSV profile with $1.1bn Icosavax deal

Drugmaker AstraZeneca on Tuesday agreed to buy vaccine developer Icosavax in a deal valued at up to $1.1 billion to bolster its respiratory syncytial virus (RSV) vaccine portfolio.

AstraZeneca to buy RSV vaccine maker Icosavax for $1.1 bln

AstraZeneca's stock is trading below its April 2022 highs, but the company is executing well and making the right moves to return and stay in growth mode. The company has managed the decline in COVID-19 revenues well, with strong performance in other product segments driving overall revenue growth. AstraZeneca has entered the obesity arena with a promising oral GLP-1 receptor agonist and has a deep and diverse pipeline of product candidates in various therapeutic areas.

AstraZeneca Is Feeling The Weight Of The Market In 2023

Gilead Sciences

Merck

This biotech giant remains a top stock for investors to buy and pays a solid 3.13% dividend.

6 Health Care Dividend Stocks To By Hand Over Fist

News for AstraZeneca Stock (AZN)